A study recently published in Lancet Oncology found ALT-803 + nivolumab safe and with early signs of efficacy in patients with mNSCLC considered PD-1-treatment resistant.
Preliminary data from the first prospective clinical trial shows higher blood-based tumor burden works as biomarker for effective atezoli-zumab treatment in non-small cell lung cancer patients.
A computer-assisted analysis of digital tissue microarray slides could soon help identify which NSCLC patients are likely to face early recurrence.
Vamsidhar Velcheti, MD, and his team are pursuing novel, targeted therapies for patients with a rare form of NSCLC.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The cancer research “dream teams” organized and funded by Stand Up to Cancer unite scientists across disciplines and specialties to accelerate the development of innovative therapies. Cleveland Clinic Cancer Center oncologist Vamsi Velcheti, MD, joins the Lung Cancer Dream Team to work on immunotherapy-related biomarkers.
Analysis finds tumor PD-L1 expression with a 5 percent cutoff is a reliable predictor of treatment success with PD-1/PD-L1 checkpoint inhibitors in the treatment of lung and other hard-to-treat cancers.
A new combination epigenetic therapy could enhance activity of immune checkpoint inhibitors in lung cancer. A proof-of-concept trial of oral tetrahydrouridine (THU)-decitabine, along with nivolumab, will begin soon at Cleveland Clinic.
Cancer and multiple sclerosis were among the focus areas in a unique session at the Biologic Therapies VI Summit in which experts from six diverse disciplines shared how biologics are being used in their specialties.